Total Thyroidectomy for Amiodarone-induced Thyrotoxicosis in the Hyperthyroid State

Abstract

Amiodarone is a potent antiarrhythmic agent, indicated for the treatment of refractory arrhythmias, which may lead to thyrotoxicosis. In these patients, thyroidectomy is a valid therapeutic option. Antithyroid therapy in the immediate preoperative setting and the subsequently accepted minimal delay until thyroidectomy have not been clearly defined yet. The aim of the present study was to show, that total thyroidectomy under general anaesthesia in patients with amiodarone-induced thyrotoxicosis (AIT) is safe without necessarily obtaining an euthyroid state preoperatively.

We conducted a retrospective cohort study of prospectively gathered data on 11 patients undergoing total thyroidectomy under general anaesthesia between January 2008 and December 2013 for AIT at our University Hospital.

All patients were preoperatively treated with carbimazole, steroids and β-receptor antagonists. Additionally, 3 patients received potassium perchlorate and in one patient carbimazole was changed to propylthiouracil. Plasmapheresis was performed in 3 patients. Only one patient was euthyroid at the time of operation. There were no significant intra- and postoperative complications, especially no signs of thyroid storm. One patient could postoperatively be removed from the cardiac transplant waiting list due to improved cardiac function.

Improvements in the interdisciplinary surgical management for AIT between cardiologists, endocrinologists, anaesthetists and endocrine surgeons provide the basis of safe total thyroidectomy under general anaesthesia in hyperthyroid state. Early surgery without long delay for medical antithyroid treatment (with its potential negative side effects) is recommended.

Key words

total thyroidectomy - amiodarone-induced thyrotoxicosis - hyperthyroidism - interdisciplinary management

• References

• 1 Houghton SG, Farley DR, Brennan MD et al. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg 2004; 28: 1083-1087 DOI: 10.1007/s00268-004-7599-6.
• 2 Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA 2007; 298: 1312-1322 DOI: 10.1001/jama.298.11.1312.
• 3 Martino E, Bartalena L, Bogazzi F et al. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-254 DOI: 10.1210/edrv.22.2.0427.
• 4 Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol 1984; 3: 1059-1071
• 5 Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997; 126: 63-73
• 6 Daniels GH. Amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 2001; 86: 3-8 DOI: 10.1210/jcem.86.1.7119.
• 7 Newman CM, Price A, Davies DW et al. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998; 79: 121-127
• 8 Bogazzi F, Bartalena L, Gasperi M et al. The various effects of amiodarone on thyroid function. Thyroid 2001; 11: 511-519 DOI: 10.1089/105072501300176471.
• 9 Tanda ML, Piantanida E, Lai A et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin Endocrinol (Oxf) 2008; 69: 812-818 DOI: 10.1111/j.1365-2265.2008.03268.x.
• 10 Bartalena L, Wiersinga WM, Tanda ML et al. Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. Clin Endocrinol (Oxf) 2004; 61: 494-502 DOI: 10.1111/j.1365-2265.2004.02119.x.
• 11 Claxton S, Sinha SN, Donovan S et al. Refractory amiodarone-associated thyrotoxicosis: an indication for thyroidectomy. Aust N Z J Surg 2000; 70: 174-178
• 12 Farwell AP, Abend SL, Huang SK et al. Thyroidectomy for amiodarone-induced thyrotoxicosis. JAMA 1990; 263: 1526-1528
• 13 Hamoir E, Meurisse M, Defechereux T et al. Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective?. World J Surg 1998; 22: 537-542 discussion 542–533
• 14 Mulligan DC, McHenry CR, Kinney W et al. Amiodarone-induced thyrotoxicosis: clinical presentation and expanded indications for thyroidectomy. Surgery 1993; 114: 1114-1119
• 15 Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab 2009; 23: 735-751 DOI: 10.1016/j.beem.2009.07.001.
• 16 Diamond TH, Rajagopal R, Ganda K et al. Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis. Intern Med J 2004; 34: 369-370 author reply 370–361 DOI: 10.1111/j.1444-0903.2004.00600.x.
• 17 Yamamoto J, Dostmohamed H, Schacter I et al. Preoperative therapeutic apheresis for severe medically refractory amiodarone-induced thyrotoxicosis: A case report. J Clin Apher 2013; DOI: 10.1002/jca.21309.
• 18 Shindo M. Surgery for hyperthyroidism. ORL J Otorhinolaryngol Relat Spec 2008; 70: 298-304 DOI: 10.1159/000149834.
• 19 Cooper DS. Hyperthyroidism. Lancet 2003; 362: 459-468 DOI: 10.1016/s0140-6736(03)14073-1.
• 20 Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet 2012; 379: 1155-1166 DOI: 10.1016/s0140-6736(11)60782-4.
• 21 Gough J, Gough IR. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. World J Surg 2006; 30: 1957-1961 DOI: 10.1007/s00268-005-0673-x.
• 22 Sutherland J, Robinson B, Delbridge L. Anaesthesia for amiodarone-induced thyrotoxicosis: a case review. Anaesth Intensive Care 2001; 29: 24-29
• 23 Brennan MD, van Heerden JA, Carney JA. Amiodarone-associated thyrotoxicosis (AAT): experience with surgical management. Surgery 1987; 102: 1062-1067
• 24 Tomisti L, Materazzi G, Bartalena L et al. Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. J Clin Endocrinol Metab 2012; 97: 3515-3521 DOI: 10.1210/jc.2012-1797.
• 25 Meerwein C, Vital D, Greutmann M et al. Total thyroidectomy in patients with amiodarone-induced hyperthyroidism: when does the risk of conservative treatment exceed the risk of surgery?. HNO 2014; 62: 100-105 DOI: 10.1007/s00106-013-2806-0.
• 26 Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. Thyroid 2002; 12: 523-525 DOI: 10.1089/105072502760143926.
• 27 Mehra A, Widerhorn J, Lopresti J et al. Amiodarone-induced hyperthyroidism: thyroidectomy under local anesthesia. Am Heart J 1991; 122: 1160-1161
• 28 Berti P, Materazzi G, Bogazzi F et al. Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. Langenbecks Arch Surg 2007; 392: 709-713 DOI: 10.1007/s00423-006-0112-y.
• 29 Blossey HC, Peitsch W. Indications for subtotal thyroidectomy in patients with amiodarone- (iodine-) induced hyperthyroidism. Wien Med Wochenschr 1988; 138: 444-447
• 30 Birkedal C, Touliatos J, Gaskin T et al. Surgical considerations for treatment of amiodarone-induced thyrotoxicosis. Curr Surg 2001; 58: 478-480
• 31 Meurisse M, Hamoir E, D’Silva M et al. Amiodarone-induced thyrotoxicosis: is there a place for surgery?. World J Surg 1993; 17: 622-626 discussion 627
• 32 Bajwa SJ, Sehgal V. Anesthesia and thyroid surgery: The never ending challenges. Indian J Endocrinol Metab 2013; 17: 228-234 DOI: 10.4103/2230-8210.109671.
• 33 Burger A, Dinichert D, Nicod P et al. Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones. J Clin Invest 1976; 58: 255-259 DOI: 10.1172/jci108466.
• 34 Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706-714 DOI: 10.1016/j.amjmed.2004.11.028.
• 35 Mittendorf EA, McHenry CR. Thyroidectomy for selected patients with thyrotoxicosis. Arch Otolaryngol Head Neck Surg 2001; 127: 61-65
• 36 Michie W, Duncan T, Hamer-Hodges DW et al. Mechanism of hypocalcaemia after thyroidectomy for thyrotoxicosis. Lancet 1971; 1: 508-514